You are here
CERID Bibliography
Substituted 2-phenylimidazopyridines: a new class of drug leads for human African trypanosomiasis. J Med Chem. 2014 ;57(3):828-35.
Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agents. Bioorg Med Chem Lett. 2013 ;23(23):6492-9.
Increased density of intraepithelial mast cells in patients with exercise-induced bronchoconstriction regulated through epithelially derived thymic stromal lymphopoietin and IL-33. J Allergy Clin Immunol. 2013 .
Regulation and function of epithelial secreted phospholipase A2 group X in asthma. Am J Respir Crit Care Med. 2013 ;188(1):42-50.
Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrob Agents Chemother. 2012 ;56(9):4914-21.
Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. Mol Biochem Parasitol. 2011 ;175(1):21-9.
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. J Med Chem. 2010 ;53(10):3887-98.
. Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. J Med Chem. 2010 ;53(19):6867-88.
Use of thermal melt curves to assess the quality of enzyme preparations. Anal Biochem. 2010 ;399(2):268-75.
Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents. Bioorg Med Chem Lett. 2009 ;19(23):6582-4.
. Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem. 2009 ;52(6):1639-47.
. Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. Chem Biol. 2009 ;16(2):181-92.
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. J Med Chem. 2009 ;52(12):3703-15.
2-Oxo-tetrahydro-1,8-naphthyridines as selective inhibitors of malarial protein farnesyltransferase and as anti-malarials. Bioorg Med Chem Lett. 2008 ;18(2):494-7.
. 2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability. J Med Chem. 2008 ;51(3):384-7.
. Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother. 2008 ;52(10):3710-7.
Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation. J Med Chem. 2008 ;51(17):5176-97.
Protein geranylgeranyltransferase-I of Trypanosoma cruzi. Mol Biochem Parasitol. 2008 ;157(1):32-43.
. Structural genomics of pathogenic protozoa: an overview. Methods Mol Biol. 2008 ;426:497-513.
C-terminal proteolysis of prenylated proteins in trypanosomatids and RNA interference of enzymes required for the post-translational processing pathway of farnesylated proteins. Mol Biochem Parasitol. 2007 ;153(2):115-24.
. Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother. 2007 ;51(10):3659-71.
Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. Mol Biochem Parasitol. 2007 ;152(1):66-71.
. Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials. J Med Chem. 2007 ;50(19):4585-605.
Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol. 2006 ;148(2):144-60.
Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J Lipid Res. 2006 ;47(2):233-40.
.